Synergistic FLT3 Mutated Proliferative Disorder Treatment System

The present inventive concept integrates crenolanib with AI, IoT, blockchain, and new materials to create a more effective and personalized treatment system for FLT3 mutated proliferative disorders.

The original patent disclosed the use of crenolanib for treating FLT3 mutated proliferative disorders, but its efficacy was limited by the lack of personalized treatment regimens, inefficient patient data management, and inadequate disease progression monitoring. The new inventive concept addresses these limitations by incorporating distinct technologies to create a more powerful system.

The new system comprises a crenolanib administration module, an AI-powered disease progression monitoring module, and a blockchain-based patient data management module. This integration enables personalized treatment regimens, real-time monitoring, and secure data management. Additionally, IoT-enabled sensors track patient response, and AI-driven analytics predict optimal dosing and treatment schedules. The composition incorporates nanoparticle-based delivery systems using new materials such as graphene, nanocellulose, or nanostructured lipid carriers, enhancing crenolanib's efficacy and bioavailability.

The new inventive concept is novel and non-obvious because it combines crenolanib with distinct technologies, creating a synergistic system that overcomes the limitations of the original patent. The integration of AI, IoT, blockchain, and new materials provides a unique solution for FLT3 mutated proliferative disorder treatment.

Alternative embodiments may include variations in the AI-powered disease progression monitoring module, such as using machine learning algorithms or natural language processing. Other variations may include different nanoparticle-based delivery systems or the incorporation of additional distinct technologies, such as gene editing or immunotherapy.

The inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the treatment of FLT3 mutated proliferative disorders. The system's ability to provide personalized treatment regimens, real-time monitoring, and secure data management addresses a significant unmet need in the market.